Results 1 to 10 of about 3,126,313 (204)

Pleural Infiltration Revealing Post-Essential Thrombocythemia Acute Myeloid Leukaemia. [PDF]

EJHaem
eJHaem, Volume 6, Issue 6, December 2025.
Muron C, Luque Paz D, Copin MC, Orvain C.   +3 more
europepmc   +2 more sources

Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study. [PDF]

Cancer Med
ABSTRACT Background Symptom management in myeloproliferative neoplasms (MPN) remains challenging despite advancements in disease‐directed therapies. This study assessed the impact of demographic, clinical, laboratory and treatment‐related variables on total symptom scores (TSS) and individual symptom scores in patients with polycythemia vera (PV ...
Khan MA, Naqvi SAA, Camoriano JK, Arana Yi CY, Andres JT, Blocher JL, Kosiorek HE, Riaz IB, Palmer JM.   +8 more
europepmc   +2 more sources

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica, 2019
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison   +5 more
doaj   +2 more sources

Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. [PDF]

Hemasphere
Abstract Health‐related quality of life (HRQoL) of patients with myeloproliferative neoplasms (MPNs) may be impaired across several domains. In this multicenter observational study, we evaluated HRQoL and symptoms in a cohort of MPN patients with validated measures, including the European Organization for Research and Treatment of Cancer Quality of ...
Caocci G, Costa A, Palandri F, Guglielmelli P, Patriarca A, Iurlo A, Tieghi A, Abruzzese E, Baldi T, Rossi E, Beggiato E, Marchetti M, Fava C, Tomassetti S, Rumi E, Fozza C, Luppi M, Pane F, Bigliardi S, Breccia M, Elli EM, Tartaglia F, Mulas O, Fazi P, Vignetti M, Vannucchi AM, Efficace F.   +26 more
europepmc   +2 more sources

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation. [PDF]

Clin Pharmacol Ther
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Jian W, Yin Y, Chen R, Xue J, Gu J, Du Z, He R, Zhou T.   +7 more
europepmc   +2 more sources

MDS/MPN With SF3B1 Mutation and Thrombocytosis but Without Ring Sideroblasts. [PDF]

Am J Hematol
American Journal of Hematology, Volume 101, Issue 1, Page 129-130, January 2026.
Hazarika B, Bain BJ.
europepmc   +2 more sources

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms. [PDF]

EJHaem
ABSTRACT Background Aquagenic pruritus (AP) is a common and distressing symptom in myeloproliferative neoplasm (MPN) patients. Methods This study assessed cytoreductive therapy effectiveness using data from 489 patients in the OBENE Observatory (NCT02897297). AP severity was tracked regularly after diagnosis.
Gall-Ianotto CL, Civi L, Pan-Petesch B, Herbreteau L, Rio L, Lambert WC, Misery L, Lippert E, Ianotto JC.   +8 more
europepmc   +2 more sources

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

Mediterranean Journal of Hematology and Infectious Diseases, 2020
Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to determine the thrombotic event, including the interaction between platelets, leukocytes and ...
Vincenzo Accurso, Marco Santoro, Salvatrice Mancuso, Angelo Davide Contrino, Paolo Casimio, Mariano Sardo, Simona Raso, Florinda Di Piazza, Alessandro Perez, Marco Bono, Antonio Russo, Sergio Siragusa   +11 more
doaj   +2 more sources

A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count

American journal of hematology/oncology, 2023
We examined the individual prognostic contribution of absolute neutrophil (ANC), lymphocyte (ALC), and monocyte (AMC) counts, on overall (OS), leukemia‐free (LFS), and myelofibrosis‐free (MFFS) survival in essential thrombocythemia (ET).
A. Tefferi, G. G. Loscocco, F. Farrukh, N. Szuber, F. Mannelli, A. Pardanani, C. Hanson, R. Ketterling, V. De Stefano, A. Carobbio, T. Barbui, P. Guglielmelli, N. Gangat, A. Vannucchi   +13 more
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source